Medical Advisory Board

RUTH L. KATZ, MD
 

RUTH L. KATZ, MD is a board certified Anatomic Pathologist and Cytopathologist who is currently Professor of Pathology, Chief of Research Cytopathology, and Director, Image Cytometry Diagnostic Laboratory at The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Dr. Katz received her medical degree from the University of Witwatersrand Medical School in Johannesburg, South Africa. She completed a residency in anatomic pathology and hematopathology at the University of Cape Town, South Africa along with a residency in anatomic pathology at New England Medical Center Tufts Hospital in Boston, Massachusetts. She served fellowships in Laboratory Medicine and Cytopathology at The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Her laboratory and research interests are in fine needle aspiration of all body sites, cytopathology of the bladder combined with special testing for molecular abnormalities by FISH, fine needle aspiration of lymphoma using a multiparameter approach, stem cell research and computer-assisted image processing for diagnosing malignancy.
Presently her major research interest is in looking at genetic susceptibility to develop lung cancer, and she has developed a panel of novel molecular markers in sputum that are designed to predict those people at high risk for developing lung cancer. She is active in numerous national and international associations including the American Society of Cytopathology, International Academy of Cytology, USCAP, and the American Association for Cancer Research. She is a well known Cytopathology lecturer and workshop leader both nationally and internationally. She has authored and co-authored close to 200 articles in leading peer review journals including The New England Journal of Medicine, American Journal of Clinical Pathology, Acta Cytologica, Diagnostic Cytopathology, Cancer, Clinical Cancer Research, and Journal of the National Cancer Institute. She also serves on the editorial board of numerous pathology journals including Cancer, Acta Cytologica, and Modern Pathology.
 

D. CRAIG ALLRED, MD
 

D. CRAIG ALLRED, MD is a board certified Anatomic Pathologist who is currently Professor and Director of Breast Pathology at Washington University School of Medicine, St. Louis, Missouri.
Dr. Allred received his medical degree from the University of Utah College of Medicine. He completed his Internship and Residency in Anatomic Pathology and his Fellowship in Immunopathology at the University of Connecticut Health Center. Dr. Allred has also held academic appointments at University of Connecticut Health Center, the University of Texas Health Science Center in San Antonio, and Baylor College of Medicine in Houston.

His research interests include translational research in breast cancer emphasizing the development and prognosis of premalignant breast disease, and prognostic and predictive biomarkers in invasive breast cancer. He is active in the College of American Pathologists, United States and Canadian Academy of Pathology, American Society of Investigative Pathology, American Association for Cancer Research, Southwest Oncology Group, and National Surgical Adjuvant Breast and Bowel Project. Dr. Allred is a well known lecturer and has also authored and co-authored many articles that can be found in leading peer review journals including Journal of the National Cancer Institute, Cancer Research, Oncogene, Clinical Cancer Research, Endocrinology, Molecular Endocrinology and the Proceedings of the Proceedings of the National Academy of Sciences.

Richard J. Cote, MD, FRCPath
Chair, Clarient Scientific Advisory Board
Specialty - Immunohistochemistry, Molecular Pathology, Genitourinary, Breast and Tumor Patholgoy

 

RICHARD J. COTE, M.D., FRCPATH is a board certified Anatomical Pathologist who has served over 20 years in senior academic, consultative, and director/clinical roles with leading hospitals and healthcare enterprises primarily in the area of cancer care.
He received his medical degree from the University of Chicago - Pritzker School of Medicine. He completed his residency at Cornell University Medical College, New York. He served a clinical fellowship in pathology at Memorial Sloan-Kettering Cancer Center, a research fellowship in Human Tumor Immunology at Memorial Sloan-Kettering Cancer Center and a fellowship in Molecular Pathology at New York University School of Medicine. He currently serves as Professor, Department of Pathology, Professor, Department of Urology, Director, Genitourinary Program, Chair, USC Biomedical Nanosciences Initiative, and Director, Laboratory of Immunology and Molecular Pathology at University of Southern California Keck School of Medicine/Norris Comprehensive Cancer Center in Los Angeles. Dr. Cote was the founder of IMPATH, Inc., served on the Board of Directors and was the Chief Strategic Consultant for the company. Dr. Cote led the reorganization of Clarient to include the focus on providing the highest quality information to pathologists and clinicians who manage patients with cancer.

Dr. Cote is an avid researcher with a major area of investigation related to cellular and molecular markers of tumor progression. He has special interests in micrometastases detection and characterization, tumor suppressor gene analysis, and molecular mechanisms of racial/ethnic variation and androgen independence in prostate cancer. He is the recipient of many awards and major research grants and holds several patents for cancer related monoclonal antibodies and for advanced diagnostic platforms. He has participated on numerous scientific advisory boards for both academic and industry related institutions. He is a well known author and lecturer and is the co-editor of Immuno Microscopy: A Diagnostic Tool for the Surgical Pathologist, and Modern Surgical Pathology. He has also served as a member, advisor and/or officer to a large number of national and international study groups, cancer programs and societies, including the National Cancer Institute. He is listed in the “Best Doctors in America” and “America’s Top Doctors”.